glp 1 for inflammatory arthritis GLP-1 Medications and Rheumatoid Arthritis: What the 2025 Research Actually Shows How a discovery in joint

2010 Apr;151(4):1473-86 Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjgren I, Andersen S, Andersen L, de Boer AS, Manova K, Barlas A, Vundavalli S, Nyborg NC, Knudsen LB, Moelck AM, Fagin JA

The agency flagged three adverse events in its FAERS database tied to compounded injectable BPC-157, including a case in which a patient developed diffuse hyperpigmentation and gingival darkening after using a blended BPC-157/TB-500 product labeled "research purposes only." The safety concern most specific to BPC-157 is its mechanism of action

To date, this study is the first to evaluate the effect of GLP-based therapies on urine oxalate, urine citrate, or urine uric acid

Prices vary widely

As expected the Fed delivered a 25 basis point cut

They usually occur in the initial phase of starting the treatment or during dose escalation, but improve over time